Collegium Pharmaceutical Debt to Equity

Collegium Pharmaceutical posts a debt-to-equity ratio of 2.75. That is above the Healthcare sector average of -8.5. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a debt-to-equity ratio near -8.5 is typical. Collegium Pharmaceutical's 2.75 is higher that level. That is roughly 132.4% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Collegium Pharmaceutical's debt-to-equity ratio of 2.75 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.

Context for COLL's debt-to-equity ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -8.5), and (3) consistency with growth and profitability. This page covers the first two; Collegium Pharmaceutical's other metric pages and overview cover the third.

Judging Collegium Pharmaceutical against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in debt-to-equity ratio easier to interpret. Start with 2.75 here, then scan peer and history charts to see if the gap is persistent.